SUMMARY The effect of nifedipine on left ventricular isovolumic relaxation and diastolic filling properties and systemic and left ventricular hemodynamics was studied in 15 patients with hypertrophic cardiomyopathy. After nidefipine (10 mg sublingually), the prolonged left ventricular isovolumic relaxation time assessed by echocardiography decreased from 112 i 26 to 83 ± 23 msec (p < 0.0001), and the left ventricular pressure decay as measured by time constant T improved from 63 + 20 to 49 ± 11 msec (p < 0.05). Left ventricular filling dynamics also improved as assessed by a return toward normal in the depressed peak rate of left ventricular diastolic filling (dimension change 72 ± 37 to 101 ± 39 mm/sec, p < 0.01) and the peak rate of posterior wall thinning (47 ± 31 to 68 + 36 mm/sec,p < 0.001). These changes were accompanied by hemodynamic evidence of improved diastolic function shown as a decrease in left ventricular end-diastolic pressure and a downward shift in the left ventricular diastolic pressure-dimension relationship, suggesting improved left ventricular distensibility. After nifedipine, there was a slight increase in heart rate and a decrease in systemic arterial blood pressure, and no depression of the left ventricular percent fractional shortening or cardiac index.
HYPERTROPHIC CARDIOMYOPATHY is associated with abnormal left ventricular diastolic function, evident as prolonged left ventricular isovolumic relaxation and impaired diastolic filling.14 The mechanisms of these abnormalities in relaxation and diastole are uncertain, but appear to be independent of the presence of a systolic outflow gradient. Kaltenbach and co-workers5 reported a salutary response to verapamil in patients with hypertrophic cardiomyopathy, and Rosing and co-workers" have recently reported similar findings. In those studies, primary emphasis was on verapamil's effects on systolic obstruction. We recently had a patient with nonobstructive hypertrophic cardiomyopathy in whom marked abnormalities in diastolic relaxation and compliance were substantially improved by administration of nifedipine.7 To pursue this observation and to assess further the role of abnormal diastolic mechanics in hypertrophic cardiomyopathy, we undertook the present prospective study of the'effects of nifedipine on left ventricular relaxation and diastolic filling in 15 patients with 'hypertrophic cardiomyopathy. The results indicate a substantial and consistent improvement in diastolic mechanics, irrespective of the presence of systolic obstruction.
Methods

Study Population
We studied 15 patients, mean age 43 years (range 17-71 years) who had hypertrophic cardiomyopathy. The diagnosis was based on typical clinical, hemodynamic, echocardiographic and angiographic findings.3 Seven patients had evidence of left ventricular outflow obstruction at rest based on echocardiographic findings of systolic anterior mitral valve motion and early aortic valve closure, and eight patients had no evidence of left ventricular outflow obstruction. All patients were in sinus rhythm, and #-adrenergic blocking agents as well as all other medications were discontinued 48 hours before the study. Each patient gave informed written consent. No complications occurred as the result of the study. Patient 1 has been described in a case report.7
Echocardiographic and Phonocardiographic Studies
Echocardiograms were recorded with an Ekoline 20 system (Smith Kline Instruments) using a 2.25-MHz transducer. Echocardiograms, phonocardiograms of aortic valve closure (A2) and ECGs were recorded on an Irex Continutrace 101 multiple-channel recorder at a paper speed of 100 mm/sec. The transducer position was kept constant at the left sternal border where continuous echocardiograms of the ventricular septum, posterior left ventricular wall and free margins of the mitral valve leaflets were clearly visible. The studies were obtained during quiet respiration before and 20 minutes after administration of nifedipine, 10 mg sublingually.
Hemodynamic Studies
In a subset of 10 patients, the echocardiographic recordings before and after pretreatment with nifedipine were obtained simultaneously with measurements of right atrial, systemic arterial and left Abbreviations: C = control before nifedipine; N = 20 minutes after nifedipine; HCM = hypertrophic cardiomyopathy; HOCM = hypertrophic obstructive cardiomyopathy; IVRT = isovolumic relaxation time; dPW/dt = peak rate of left ventricular diastolic posterior wall thinning; APW = left ventricular posterior wall diastolic thickness change; dDLv/dt = peak rate of increase ofleft ventricular dimension during diastole; ADLv = left ventricular dimension change during diastolic filling; RR = cycle length; EDD = left ventricular end-diastolic dimension; ESD = end-systolic dimension; FS = fractional shortening of the left ventricular minor dimension. ventricular pressures and determination of cardiac output. Cardiac catheterization was carried out using the brachial or femoral approach. Systemic arterial and right atrial pressures were measured with a fluidfilled catheter system and strain-gauge transducers8 and referenced to atmosphere at the midchest level. Left ventricular pressure was recorded with a micromanometer-tip catheter (Millar Instruments) calibrated externally against a mercury reference and matched simultaneously against luminal pressure. Cardiac output was measured by the Fick method. Selective coronary arteriography was performed in the 10 invasively studied patients. Only patient 7 had coronary artery disease, which consisted of significant circumflex and right coronary artery stenoses.
Data Analysis
Three consecutive beats with clearly identified septal and posterior wall endocardial and epicardial echoes were analyzed in control conditions and after the administration of nifedipine.' Left ventricular posterior wall endocardium, septal wall endocardium and posterior wall epicardium were digitized every 5 msec from the peak of the R wave of the ECG to the pea-k of the R wave of the subsequent beat. Data were digitized using a hand-controlled cursor (Graph Pen) and processed by a Tektronix 4051 computer system to provide left ventricular internal diameter and posterior wall thickness data. A polynomial (sixth order) fitted to the diastolic data points was used to calculate internal diameter filling rates and posterior wall thinning velocities. Agreement between the time data points and'the points calculated from the polynomial fit was excellent (r > 0.99). The peak rate of left ventricular diastolic posterior wall thinning (dPW/dt)' and the peak rate of left ventricular internal dimension change during diastole (dDLv/dt) were derived from this computer analysis. The left ventricular isovolumic relaxation time (IVRT) was calculated as the interval between the first high-frequency component of the aortic valve closure sound (A2) and the opening of the mitral valve leaflets on the echocardiogram. In our laboratory the control values for normal subjects (mean ± SD) are: dPW/dt = 82 ± 11 mm/sec; dDLV/dt = 118 i 7 mm/sec; IVRT = 60 i 7 msec.
The fractional shortening of the left ventricular internal dimension was calculated as EDD -ESD/ EDD X 100, where EDD = end-diastolic dimension and ESD = end-systolic dimension.
The time constant of left ventricular pressure decay (T) was determined from the downslope of the left ventricular micromanometer pressure on three consecutive beats. Left ventricular pressure was digitized using a hand-controlled cursor at 5-msec intervals from peak negative dP/dt to the pressure on the downslope that was equal to the left ventricular end-diastolic pressure. A polynomial (sixth order) fit (r > 0.99) was used to calculate time constant T because of the poor agreement (r < 0.95) between the true data CIRCULATION 500 points and the points calculated from an exponential fit" or a modified exponential fit with nonzero reference pressure.'0'"
Statistical Analysis
The interobserver and intraobserver variability coefficients were 2.3% and -1.9%, respectively, for the left ventricular dimension change during diastolic filling, 3.2% and 2.6% for the rate of diastolic posterior wall thinning, and 2.4% and 2.0% for the isovolumic relaxation time. Interobserver and intraobserver variability coefficients' were calculated using, respectively, the variance of the means and the mean variance.'2 The statistical significance of the mean values ± SD was assessed by t test.
Results
Echocardiographic Assessment of Diastolic Function
The individual echocardiographic measurements before and after nifedipine are listed in table 1. Figure  1 shows representative echocardiograms recorded at the level of the mitral valve and the left ventricular cavity before and after nifedipine. After nifedipine, the left ventricular isovolumic relaxation time decreased from 1 12 ± 26 to 83 ± 23 msec (p < 0.0001) ( fig. 2 ). Nifedipine was also associated with a significant increase in the peak rate of left ventricular diastolic posterior wall thinning, accompanied by an absolute increase in the change in left ventricular posterior wall thickness from end-systole to end-diastole (table 1) . After nifedipine, the peak rate of left ventricular internal dimension change during diastole, which reflects left ventricular filling, also improved markedly. Because the mean cycle length (RR) and the absolute duration of diastole shortened after nifedipine, there were no significant differences in the total increase in left ventricular dimension during diastolic filling or in left ventricular end-diastolic dimension after-nifedipine compared with the control. There was no increase in 'left ventricular end-systolic dimension or depression of the fractional shortening'of the left ventricular internal dimension after nifedipine.
Hemodynamic measures obtained simultaneously with echocardiographic recording in the subset of 10 patients studied during catheterization are 'listed in table 2. As a group, these patients had a small increase in heart rate and a decrease in sys'tolic arterial pressure after nifedipine. The response of cardiac' index and systemic vascular resistance varied from patient to patient; in the subgroup of 10 patients, cardiac index did not change, but systemic vascular resistance decreased after nifedipine. Only one of eight patients without a resting left ventricular outflow tract gradient at cardiac catheterization developed a gradient after nifedipine, whereas the two patients wh'o had a resting gradient in the control period showed a decrease in gradient.
For the group, there was a small but significant decrease in left ventricular end-diastolic pressure after nifedipine. Two patients had an increase, one showed no change, and seven had a decrease in left ventricular end-diastolic pressure, including four patients whose control left ventricular end-diastolic pressure was greater than 20 mm Hg ( fig. 3) . The left ventricular pressure-dimension relationship was analyzed to determine the mechanism of the decrease in left ventricular end-diastolic pressure in these patients. In one patient, this decrease was related to a reduction of left ventricular end-diastolic dimension, and in the other patients to a downward shift in the left ventricular dia- C  N  C  N  C  N  C  N  1  56  55  145  105  110  85  0  0  2  60  60  144  120  105  85  0  35  3  73  82  117  114  86  82  0  0  4  63  100  116  107  86  88  58  21  5  80  100  126  105  110  85  0  0  6  74  94  130  110  102  88  0  0  7  100  100  108  107  80  80  41 dynamics; thus, the prolongation of the left ventricular filling rates is largely determined by the prolongation of diastolic thinning of the left ventricular posterior wall, as in our patients. In addition, several of our patients showed abnormalities of the left ventricular diastolic pressure wave form itself, suggesting the existence of a markedly prolonged relaxation phase. Murgo and co-workers14 have reported similar observations. The etiology of the abnormal diastolic properties in hypertrophic cardiomyopathy is unknown. St. John Sutton and co-workers2 suggested that the development of impaired diastolic thinning of the left ventricular posterior wall may reflect an extension of the myopathic process beyond the septum to the left ventricular posterior free wall. Our study confirms the observation of Hanrath and co-workers"' that abnormalities of diastolic relaxation and filling in hypertrophic cardiomyopathy are in part dynamic, and extends our initial observation7 that nifedipine can favorably modify diastolic dysfunction in this disorder.
The mechanism that may account for the beneficial effects of nifedipine in hypertrophic cardiomyopathy is unclear. Nifedipine is a 1,4-dihydropyridine derivative that antagonizes slow channel calcium flux into both myocardial cells and the smooth muscle cells of coronary and systemic arteries." Several possible pharmacologic effects of nifedipine could account for the benefits seen in this study: (1) a direct effect on the myocardium by altering myocardial calcium metabolism; (2) an effect on coronary blood flow; and (3) alteration of left ventricular loading conditions secondary to systemic arterial dilation.
In experimental animal studies, calcium-channel blockers cause a dose-dependent depression of the rate of calcium-dependent ATP consumption and tension development and diminution of myocardial oxygen 504 CIRCULATION Alternatively, nifedipine could exert an effect on the myocardium by altering calcium content or transport in the hypertrophied myocardium. In cultured beating myocardial cells, progressive calcium overload initially elicits a hypercontractile state followed by the development of impaired myocardial cell relaxation and impaired systolic shortening, which can be reversed by administration of calcium-channel blockers.'8 Further, the hereditary hypertrophic cardiomyopathy of the Syrian hamster is reported to be associated with increased myocardial calcium uptake and content, and the development of both metabolic and pathologic changes can be prevented by the administration of calcium-channel blockers.' Although substantial differences clearly exist between this animal model and hypertrophic cardiomyopathy in humans, Kaltenbach suggested that the abnormal hemodynamic properties in this disorder may be related to an increase in the availability of intracellular calcium.20 These considerations support the speculation that the improvement in diastolic function after nifedipine in patients with hypertrophic cardiomyopathy may be related to a direct effect on myocardial transport and metabolism of calcium.
In addition to possible direct effects on the hypertrophied myocardium, nifedipine could exert a 30 and an increase in coronary blood flow to the subendocardium of the hypertrophied muscle. Finally, nifedipine's pharmacologic effects include systemic arterial dilation.,' In the present study, nifedipine administration was associated with a reduction in systemic arterial blood pressure and systemic vascular resistance and a slight increase in heart rate. A change in left ventricular relaxation can occur in association with changes in heart rate per se.32 The effect of altered left ventricular loading conditions on isovolumic relaxation in both humans and controlled animal preparations is controversial.33 34 However, an increase in heart rate is very unlikely to account for the results observed in this study. The effect of nifedipine on heart rates was highly variable, yet all patients had improved isovolumic relaxation and diastolic filling dynamics. Reduced left ventricular afterload would not be expected to cause a reduction in venous return and left ventricular end-diastolic pressure36 or a downward shift in left ventricular pressuredimension relationship.36f Further, the process of isovolumic relaxation appears to be relatively independent of left ventricular loading conditions.9 Altered right-heart loading conditions are unlikely to account for any improvement in diastolic function, as right atrial pressure did not change after nifedipine; in previous studies, nifedipine did not promote venous pooling or reduce right-heart loading. 37' 88 Additional studies are needed to clarify the relationship, if any, between alterations of diastolic properties and the dynamic left ventricular outflow gradient in patients with hypertrophic cardiomyopathy. In this study, nifedipine elicited a resting gradient in one of eight patients studied during cardiac catheterization, and a reduction in resting intracavitary gradient occurred in other patients. An increase in left ventricular outflow gradient possibly related to a decrease in systemic vascular resistance has occurred in some patients after verapamil.' 39 The more potent vasodilatory action of nifedipine compared with verapamil could potentially offset nifedipine's beneficial myocardial effects and result in a net increase in left ventricular outflow gradient. However, the lack of drugrelated conduction disturbances and sinus node depression might be a relative advantage of nifedipine over verapamil in treating patients with hypertrophic cardiomyopathy.
In conclusion, nifedipine favorably modifies the echocardiographic and hemodynamic evidence of prolonged left ventricular isovolumic relaxation and abnormal left ventricular diastolic filling in patients with severe hypertrophic cardiomyopathy. The improvement in diastolic function after nifedipine was not associated with depressed left ventricular systolic performance. Further studies are indicated to clarify whether the beneficial effects of nifedipine in patients with hypertrophic cardiomyopathy are due to a direct myocardial effect or diminished subendocardial ischemia associated with severe left ventricular hypertrophy.
